Amarin (AMRN) shares are surging this morning on positive results for the company’s fish-oil treatment for people at risk of heart disease.The drug AMR101 lowered levels of triglyceride (a fat-like substance found in blood) without increasing bad cholesterol in patients on a statin therapy such as Lipitor the company said. The drug was rejected by US Food and Drug Administration officials in 2007 because it increased LDL or bad cholesterol in some patients.Shares of the company shot up 80% to $15.78 in morning trading Monday. They have increased eightfold in the past year.Amarin plans to apply for US approval ...